Dr. Srinivasan Narasimhan, MD

Dr. Narasimhan practices at Rockefeller Neuroscience Institute - Neurology - HOPD in Morgantown, West Virginia.

Dr. Narasimhan's NPI, 1427075258, was assigned on July 16, 2006. Dr. Narasimhan holds West Virginia license 18444.

Dr. Narasimhan's primary practice is Rockefeller Neuroscience Institute - Neurology - HOPD, at 33 Medical Center Dr, Morgantown, WV 26505.

Dr. Narasimhan's primary practice is Rockefeller Neuroscience Institute - Neurology - HOPD in Morgantown, West Virginia. Dr. Narasimhan is also affiliated with Charleston Area Medical Center General Hospital. The medical group on file is University Health Associates. Dmand AI also links Dr. Narasimhan to 2 more hospitals, 2 group practices and clinics, 1 physician office and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Narasimhan practices, 7 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Narasimhan's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Narasimhan is licensed in West Virginia.

CMS data shows 2,312 Medicare services from Dr. Narasimhan across 20 procedure codes in 2024, for 1,186 Medicare patients. Medicare paid $105,144 for them.

CMS counts 1,186 Medicare patients who saw Dr. Narasimhan in 2024. The largest group is 65 to 74, with 507 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 15% are also on Medicaid. Their average risk score is 1.69, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Narasimhan's median patient age at 70, with 52% women.

In 2024, Dr. Narasimhan wrote 3,185 Medicare Part D claims for 444 patients. 80% of them were for generic drugs. CMS names the drug for 3,002 of them, across 40 drugs with 11 or more claims each, at $630,720 in total drug cost. In 2023, CMS named 3,537 claims across 45 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Narasimhan for performance year 2024, reported through an alternative payment model (APM). Dr. Narasimhan accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 44 papers to Dr. Narasimhan, published from 2011 to 2025. 2024 was the busiest year, with 6. The most frequent topics are Checklist, Double-Blind Method and Endodontics. Dr. Narasimhan has published most often in Acta Crystallogr Sect E Struct Rep Online. Dr. Narasimhan's most frequent co-authors are Judy L. Aschner, MD, Whitney Elena Lieb, MD and Brenda Poindexter, MD.

CMS Open Payments shows 27 general payments to Dr. Narasimhan from 12 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 98% of the total. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) paid the most, $106.